xoma8ka_082807.htm
 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C.  20549
 
FORM 8-K/A
(Amendment No. 1)
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of Earliest Event Reported):  August 28, 2007
 
XOMA LTD.
(Exact name of registrant as specified in its charter)
 
BERMUDA
(State or other jurisdiction of incorporation)
 
0-14710
  
52-2154066
(Commission File Number)
  
(IRS Employer Identification No.)
     
2910 Seventh Street, Berkeley, California
  
94710
(Address of principal executive offices)
  
(Zip code)
     
Registrant's telephone number, including area code
  
(510) 204-7200


(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[   ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[   ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[   ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[   ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 
 

Item 1.01.  Entry into a Material Definitive Agreement
 
As announced on August 28, 2007, XOMA has licensed to Pfizer Inc. non-exclusive, worldwide rights to XOMA’s patented bacterial cell expression (BCE) technology for phage display and other research, development and manufacturing of antibody products.  Under the terms of the license agreement, XOMA will receive an upfront, non-dilutive cash payment of $30 million and milestone, royalty and other fees on future sales of all products subject to this license, including products currently in late-stage clinical development.
 
A copy of the license agreement is attached hereto as Exhibit 2 and is incorporated herein by reference.
 
Item 9.01.  Exhibits
 
1.           Press Release dated August 28, 2007.*
 
2.
License Agreement, effective as of August 27, 2007, by and between XOMA Ireland Limited and Pfizer Inc. (with certain confidential information omitted, which omitted information is the subject of a confidential treatment request and has been filed separately with the Securities and Exchange Commission).
 
___________________
 
*           Previously filed.
 

 

 

 
 
 

SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Dated:  September 13, 2007                                                                           XOMA LTD.
 
 
 
By:  /s/  Christopher J. Margolin
 
 
        Christopher J. Margolin
        Vice President, General
        Counsel and Secretary
 
 

 
 
 

EXHIBIT INDEX
 
Number                      Description
 
1.           Press Release dated August 28, 2007. *
 
2.
License Agreement, effective as of August 27, 2007, by and between XOMA Ireland Limited and Pfizer Inc. (with certain confidential information omitted, which omitted information is the subject of a confidential treatment request and has been filed separately with the Securities and Exchange Commission).
 
___________________
 
*           Previously filed.